Join to View Full Profile
9320 SR-54 ENew Port Richey, FL 34655
Phone+1 727-842-8411
Fax+1 877-917-2336
Dr. Perez is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Bradford Perez, MD, is a Radiation Oncologist based in New Port Richey, FL, specializing in stereotactic radiosurgery, thoracic oncology, and breast radiation oncology. He completed his residency in Radiation Oncology at Duke University Hospital in 2015 and earned his MD from Duke University School of Medicine in 2010. Dr. Perez currently practices at the Florida Cancer Specialists and Research Institute and has been an Assistant Member at H. Lee Moffitt Cancer Center since 2015. His publications include research in journals such as JTO Clinical and Research Reports and Immunity. He has also been involved in clinical trials investigating treatments for non-small cell lung cancer and extensive-stage small cell lung cancer.
Education & Training
Duke University HospitalResidency, Radiation Oncology, 2011 - 2015
Duke University School of MedicineClass of 2010, MD, AOA
Certifications & Licensure
FL State Medical License 2015 - 2027
NC State Medical License 2010 - 2015
American Board of Radiology Radiation Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification PowerChart (Clinical), Cerner Corporation, 2016-2017
- CMS Meaningful Use Stage 1 Certification HealtheLife and PowerChart, Cerner Corporation, 2016-2017
- CMS Meaningful Use Stage 1 Certification FairWarning® Patient Privacy Monitoring, FairWarning Technologies, LLC, 2016-2017
Clinical Trials
- Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2017 Feb 13
- Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2018 Nov 20
Publications & Presentations
PubMed
- 1 citationsSIRT2-mediated deacetylation of LCK governs the magnitude of T cell receptor signaling.Imene Hamaidi, Pingyan Cheng, Soo Young Jun, Alak Manna, Min-Hsuan Wang
Nature Immunology. 2026-02-01 - 6 citationsCD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL expansion.Renata Ariza Marques Rossetti, Leticia Tordesillas, Matthew S Beatty, Junior Cianne, Elena Martinez Planes
Journal for Immunotherapy of Cancer. 2025-04-08 - 1 citationsUnveiling the Molecular Features of SCLC With a Clinical RNA Expression Panel.Hilal Ozakinci, Aileen Y Alontaga, Pedro Cano, John M Koomen, Bradford A Perez
JTO Clinical and Research Reports. 2024-11-01
Professional Memberships
- Member
- Member
External Links
- Bradford Perez-FCShttp://www.flcancer.com/staff/bradford-perez
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
